Celcuity (CELC) to Release Quarterly Earnings on Thursday

Celcuity (NASDAQ:CELC) will issue its quarterly earnings data after the market closes on Thursday, November 14th. Analysts expect the company to announce earnings of ($0.65) per share for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link.

Celcuity (NASDAQ:CELC) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.62) earnings per share for the quarter, beating the consensus estimate of ($0.71) by $0.09. During the same period in the prior year, the firm earned ($0.66) EPS. On average, analysts expect Celcuity to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Celcuity Stock Performance

NASDAQ CELC opened at $14.94 on Wednesday. The company has a fifty day moving average price of $15.25 and a 200-day moving average price of $16.08. The firm has a market cap of $553.23 million, a price-to-earnings ratio of -5.45 and a beta of 0.76. The company has a debt-to-equity ratio of 0.54, a current ratio of 14.95 and a quick ratio of 14.95. Celcuity has a 1 year low of $10.43 and a 1 year high of $22.19.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on CELC shares. HC Wainwright reaffirmed a “buy” rating and issued a $27.00 price objective on shares of Celcuity in a research report on Thursday, August 15th. Leerink Partners began coverage on Celcuity in a research report on Monday, July 22nd. They set an “outperform” rating and a $29.00 price target for the company. Needham & Company LLC reiterated a “buy” rating and set a $23.00 price target on shares of Celcuity in a report on Thursday, August 15th. Lifesci Capital assumed coverage on Celcuity in a research note on Monday, August 26th. They issued an “outperform” rating and a $27.00 price objective for the company. Finally, Leerink Partnrs upgraded Celcuity to a “strong-buy” rating in a research note on Monday, July 22nd. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Buy” and an average target price of $29.17.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.